NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
2/8 — Basic
ABACAVIR SULFATE; LAMIVUDINE (abacavir sulfate; lamivudine) by Viatris (2) is fixed-dose combination of the hiv‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see microbiology ()]. Approved for hiv-1 infection in adults, weighing at least 6 kg.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Abacavir sulfate; lamivudine is a fixed-dose combination antiretroviral therapy for HIV-1 infection in adults and children weighing at least 6 kg. This two-drug nucleoside reverse transcriptase inhibitor (NRTI) combination works by inhibiting HIV-1 reverse transcriptase to reduce viral replication. The oral tablet formulation provides simplified dosing for treatment-naive and experienced HIV-1 patients.
Pre-Launch
Pre-launch stage indicates imminent go-to-market activities with scaling team requirements for commercial, medical affairs, and market access functions.
Mechanism of Action
fixed-dose combination of the HIV‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see Microbiology ()].
Indications (2)
Worked on ABACAVIR SULFATE; LAMIVUDINE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.